Loading stock data…
$84.95
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $25.12M↑ | $10.73M↑ | $6.16M↑ | $143,000↓ | $1.03M |
| Gross Profit | $24.96M↑ | $10.53M | — | — | $1.03M |
| Operating Income | -$132.46M↑ | -$140.38M↓ | -$133.67M↑ | -$142.59M↓ | -$129.11M |
| Net Income | -$120.86M↑ | -$127.84M↓ | -$122.81M↑ | -$130.09M↓ | -$115.64M |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidat...